Pfeuffer, Steffen http://orcid.org/0000-0001-5171-4845
Schmidt, Rene
Straeten, Frederike Anne
Pul, Refik
Kleinschnitz, Christoph
Wieshuber, Marinus
Lee, De-Hyung
Linker, Ralf A.
Doerck, Sebastian
Straeten, Vera
Windhagen, Susanne
Pawlitzki, Marc
Aufenberg, Christoph
Lang, Michael
Eienbroeker, Christian
Tackenberg, Björn
Limmroth, Volker
Wildemann, Brigitte
Haas, Jürgen
Klotz, Luisa
Wiendl, Heinz
Ruck, Tobias
Meuth, Sven G.
Funding for this research was provided by:
Sanofi Genzyme (ALAIN01)
Competence Network Multiple Sclerosis (01GI1603D)
Article History
Received: 17 July 2018
Revised: 4 November 2018
Accepted: 8 November 2018
First Online: 16 November 2018
Compliance with ethical standards
:
: Steffen Pfeuffer: received travel reimbursements from Sanofi-Genzyme and Merck and honoraria for lecturing from Sanofi Genzyme, Biogen and Mylan. Rene Schmidt: declares no conflicts of interest. Frederike Anne Straeten: declares no conflicts of interest. Refik Pul: received travel reimbursements from Merck, research support by Novartis, speaker honoraria from Merck Serono, Biogen, Novartis, Sanofi-Genzyme, Mylan and Roche. Christoph Kleinschnitz: received travel reimbursements, honoraria for lecturing and research support from Ablynx, Amgen, Bayer Vital, Bristol-Mayers Squibb, Biotronik, Boehringer Ingelheim, Biogen, CSL Behring, Daiichi-Sankyo, Desitin, Eisai, Ever Pharma, Sanofi Genzyme, Merck Serono, Mylan, Medday, Novartis, Pfizer, Roche, Siemens, Stago and Teva. Marinus Wieshuber: declares no conflict of interest. De-Hyung Lee: received compensation for activities with Biogen, Merck, Novartis, Roche, and Sanofi-Genzyme. Ralf A. Linker: received compensation for activities with Biogen, Merck, Novartis, Roche, and Sanofi-Genzyme. Sebastian Doerck: reports no conflicts of interest. Vera Straeten: received travel reimbursements from Novartis, Merck and Biogen and honoraria for lecturing from Sanofi Genzyme, Biogen and Novartis. Susanne Windhagen: declares no conflict of interest. Marc Pawlitzki: received honoraria for lecturing and travel reimbursements from Biogen, Sanofi Genzyme, Merck Serono, Roche and Novartis. Christoph Aufenberg: received travel reimbursements from Bayer. Michael Lang: received travel grants, honoraria for lecturing, financial research support and consultancy fees from Teva, Merck Serono, Sanofi Genzyme, Novartis, Bayer and Biogen. Christian Eienbroeker: received honoraria for lecturing from Bayer, Biogen, and CSL Behring. Björn Tackenberg: received personal speaker honoraria and consultancy fees as a speaker and advisor from Bayer Healthcare, Biogen, CSL Behring, GRIFOLS, Merck Serono, Novartis, Octapharma, Roche, Sanofi Genzyme, TEVA and UCB Pharma. Volker Limmroth: received honoraria as speaker, AD-Board member or research support from Antisense, Bayer, Biogen, Boehringer, Sanofi Genzyme, Novartis, Pfizer, Roche and Teva. Brigitte Wildemann: received grants and personal fees from Biogen, Merck Serono, Sanofi Genzyme, Novartis and Teva, and personal fees from Bayer Healthcare. Jürgen Haas: declares no conflict of interest. Luisa Klotz: received compensation for serving on scientific advisory boards from Sanofi Genzyme and Novartis, honoraria for lecturing and travel reimbursements from CSL Behring, Merck Serono, Biogen, Sanofi Genzyme, Novartis, and research support from Biogen and Novartis. Heinz Wiendl: received compensation for serving on Scientific Advisory Boards/Steering Committees from Bayer, Biogen, Sanofi Genzyme, Merck Serono and Novartis, honoraria for lecturing and travel reimbursements Bayer, Biogen, CSL Behring, EMD Serono, Fresenius Medical Care, Sanofi Genzyme, Merck Serono, Omniamed, Novartis and Sanofi Aventis. He received compensation as a consultant from Biogen, Merck Serono, Novartis, Roche and Sanofi Genzyme and research support from Bayer, Biogen, Merck Serono, Novartis, Sanofi Genzyme and Teva. Tobias Ruck: received travel reimbursements from Merck Serono and financial research support from Sanofi Genzyme and Novartis and honoraria for lecturing from Sanofi Genzyme, Roche, Biogen, Merck Serono and Teva. Sven G. Meuth: received honoraria for lecturing, travel reimbursements and financial research support from Bayer, Biogen, Sanofi Genzyme, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi Aventis, UCB and Teva. The submitting author hereby declares that he takes responsibility for conduction and analysis of the data and that he had full access to all study data. The submitting author furthermore declares that there are no competing interests concerning these data and that the authors have all rights to publish the data. The submitted manuscript does not contain data that have been published in any other journal. The authors have no related articles under submission.
: The local institutional review board (IRB) has approved the conduction of this trial. Further details are listed in the “Methods” chapter.